SCHEMBL513188

SCHEMBL513188

CC(C)(C)OC(=O)N1CCC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
KDM1A O60341 1/20 0.40
ESR2 Q92731 1/20 0.39
CTSK P43235 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
NR1H2 P55055 1/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
HPGD P15428 1/20 0.37
UCHL1 P09936 1/20 0.36
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
BUB1 O43683 1/20 0.36
GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205421 0.89 LMNA (0.48) USP2SMN1; SMN2CHRM2CHRM1CHRM3
Tetrahydrofuran SCHEMBL28264888 0.88 USP2 (0.50) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL7495565 0.87 LMNA (0.47) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL42476 0.87 SMN1; SMN2 (0.48) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL138570 0.87 USP2 (0.40) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL31551856 0.85 SMN1; SMN2 (0.50) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL5421438 0.85 SMN1; SMN2 (0.50) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL7065400 0.83 CYP2D6 (0.36) SMN1; SMN2KDM1AKDM4EMAPTTHRB
SCHEMBL11995195 0.83 USP2 (0.56) USP2SMN1; SMN2CHRM2CHRM1CHRM3
SCHEMBL22578666 0.82 CHRM2 (0.37) USP2SMN1; SMN2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112225739-B Preparation method of azetidine compound 宜昌东阳光制药有限公司 2024-04-26 CN claimed
EP-4025575-B1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-12-17 EP disclosed
CN-114728918-B RIP1 inhibitory compounds and methods of making and using the same 里格尔药品股份有限公司 2025-06-17 CN disclosed
EP-4025568-B1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-05-14 EP disclosed
EP-4025574-B1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-05-07 EP disclosed
CN-114728958-B RIP1 inhibitory compounds and methods of making and using the same 里格尔药品股份有限公司 2025-05-02 CN disclosed
US-20250115591-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2025-04-10 US disclosed
US-20240383874-A1 BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. 2024-11-21 US disclosed
US-20240368119-A1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS, INC. 2024-11-07 US disclosed
US-20240254138-A1 TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-08-01 US disclosed
WO-2010052255-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-05-14 WO disclosed
US-7378415-B2 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2008-05-27 US disclosed
US-20080009494-A1 Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2008-01-10 US disclosed
US-20070299060-A1 Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2007-12-27 US disclosed
CN-101031554-A Benzoxazine and quinoxaline derivatives and uses HOFFMANN LA ROCHE (CH) 2007-09-05 CN disclosed
EP-1797051-A1 BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES F. Hoffmann-Roche AG (CH) 2007-06-20 EP disclosed
US-20060106012-A1 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC 2006-05-18 US disclosed
WO-2006037481-A1 BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES F.HOFFMANN-LA ROCHE AG (CH) 2006-04-13 WO disclosed
WO-2004041795-A1 NOVEL INHIBITORS OF DIPEPTIDYL PEPTIDASE IV GUILFORD PHARMACEUTICALS INC. (US) 2004-05-21 WO disclosed
EP-0639577-B1 Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents BRISTOL MYERS SQUIBB CO (US) 2002-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368119-A1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIPK1, RIPK2, RIPK3 USP2 1082/4885SMN1; SMN2 1682/4885CHRM2 4692/4885
US-20240254138-A1 TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS CDK7, CDK2, CCNK USP2 3216/4885SMN1; SMN2 3137/4885CHRM2 4811/4885
US-20070299060-A1 Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses MKI67, PCNA, TK1 USP2 3067/4885SMN1; SMN2 1904/4885CHRM2 4801/4885
US-20080009494-A1 Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses MKI67, PCNA, TK1 USP2 3067/4885SMN1; SMN2 1904/4885CHRM2 4801/4885
US-20240383874-A1 BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF AR, SF3B5, SF3B1 USP2 4468/4885SMN1; SMN2 884/4885CHRM2 4764/4885
US-20250115591-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 USP2 2264/4885SMN1; SMN2 2436/4885CHRM2 1374/4885
US-20060106012-A1 Benzoxazine and quinoxaline derivatives and uses thereof XDH, PDHX, HAX1 USP2 4328/4885SMN1; SMN2 3537/4885CHRM2 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.